MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension

  • MannKind Corporation MNKD and United Therapeutics Corporation UTHR have announced that the FDA has accepted for review the marketing application of Tyvaso DPI (inhaled treprostinil).
  • Under priority review status, the application seeks approval to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
  • The agency's review will complete in October and indicated that they had not identified any potential review issues at this time.
  • Tyvaso DPI is a next-generation dry powder formulation of Tyvaso. If approved, Tyvaso DPI is expected to provide a more convenient method of administration as compared with traditional nebulized Tyvaso therapy.
  • Price Action: MNKD shares are up 11% at $4.55 during the premarket session on the last check Wednesday, while UTHR closed at $178.45 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!